Guardant Health, Ohio State University Partner on Blood-Based Colon Cancer Screening Study
OSU investigators will offer the Guardant Shield assay to patients via mobile phlebotomists, studying adoption rates among approximately 300 individuals.
Guardant Health Submits Colorectal Cancer Screening Test to FDA for Premarket Approval
The firm's application is supported by data from the ECLIPSE study, which compared results of the Shield test to colonoscopy findings in 20,000 individuals.
AACC Issues New Cervical Cancer Detection Guidance
The new guidance includes an ideal lab report template and synthesizes guidelines previously issued by three other organizations.
Company officials discussed the outlook for 2023 after reporting fourth quarter and full-year 2022 financial results in line with earlier projections.
Obesity Linked to DNA Damage, Breast Cancer Risk in Women Harboring BRCA Mutations
The research suggests that maintaining a lower body weight or pharmacologically targeting estrogen or metabolic dysfunction may reduce the risk of breast cancer in these women.